Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Diphosphonates
  • Imidazoles
  • Osteoporosis
  • Prostatic Neoplasms

abstract

  • Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer.

publication date

  • June 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/01.ju.0000063820.94994.95

PubMed ID

  • 12771706

Additional Document Info

start page

  • 2008

end page

  • 12

volume

  • 169

number

  • 6